Cyclin-Dependent Kinase (CDK) Inhibitors Therapeutics Pipeline Projects Vast Growth Ahead     |    CAD Software Market to Reach $11,097 Million by 2023     |    Friedreich’s Ataxia (FRDA) Therapeutics Pipeline to Receive Various Drug Designations from the USFDA and EMA in the Coming Years
P&S Market Research - A market research firm

Estrogen Receptor-Positive Breast Cancer Pipeline Analysis

P&S Market Research-Estrogen Receptor Positive Breast Cancer Pipeline Analysis report

Estrogen Receptor-Positive Breast Cancer Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Published: March 2017
Report Code: LS10796
Available Format: pdf
Pages: 173

Pipeline Overview

Estrogen Receptor-Positive (ER+) breast cancer is the most common type of breast cancer diagnosed and it refers to the cancer cells that have receptors on their surface to bind with estrogen. Breast cancer is said to be estrogen receptor-positive (ER+), if it contains estrogen that receives signals from estrogen to promote cell growth. Breast cancer is a syndrome that affects breast tissues and cells in the breast grow in an uncontrollable manner forming a tumor, which can be felt as a lump or can be viewed under x-ray. Majority of breast cancers begin in lobules, tissues which are made up of glands for milk production and ducts that connect the lobules to the nipple. The risk factor of the disease includes personal or family medical history or certain changes in their genes. The increased life expectancy, shift toward urbanization and adoption of western lifestyles are the common factors instigating the risk of development of breast cancer. Early detection of ER+ breast cancer is important for the improvement of breast cancer outcome and survival.

Breast cancer still remains the major cause of deaths among women, but in coming years, it is likely that mortality and morbidity would increase in much less proportion than the standard reckoning, and there is even a possibility of decrease in the rate of occurrence of the disease. There are several reasons that are likely to contribute to the same, such as progress in screening/diagnosis, which leads to early detection of the tumor, making it more acquiescent for treatment.

The second reason can be progress in the pharmacological treatment and incursion of new drugs such as tamoxifen, which have been highly effective in the treatment of contralateral breast cancer in ER+ patients.

Thirdly, the pipeline is very profuse; new therapeutic agents are under development, which are likely to become available in next few years.

Pipeline Analysis

As of February 2017, the ER+ breast cancer pipeline comprised of approximately 74 drug candidates in different stages of development.

 

NUMBER OF ER+ BREAST CANCER DRUG CANDIDATES UNDER DEVELOPMENT (2017)

Estrogen Receptor Positive Breast Cancer Pipeline Analysis

 

Competitive Landscape

Some of the key players developing drugs for ER+ breast cancer includes Chipscreen Biosciences, Ltd., Eli Lilly & Company, Genentech, Inc. and others.

Scope for Customization

P&S Market Research offers customization as per specific business requirements of clients. Illustrative customization within the scope of this report includes:

  • Market Forecast – Market analysis and forecast for the drug candidates in the last stage of development
  • Epidemiology Forecast - Epidemiology analysis and forecast.
  • Company Profiles – Wider company coverage in terms of detailed analysis or additional company profiles

Place An Order

Single User License

Single User License authorizes access of the publication to single user, i.e. the buyer of the report.

2500
Group License

Group License authorizes access of the publication upto 5 users.

3250
Enterprise License

Enterprise License provides right to distribute copies of the publication across the organization and its subsidiaries.

6000
down-arrow

Pre-Purchase Enquiry

Contact Us

  • U.S. Center : 347 5th Ave. #1402- 210 New York City, NY 10016 United States
  • Asian Center : B-28, Sector 1, Noida, U.P. - 201301 India.

Secure Online Payments

  • Payment